Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). The FDA's RMAT designation is designed to support the development and evaluation of regenerative medicines, including genetic therapies, with the intention of addressing serious or life-threatening diseases that have unmet medical needs. RMAT designation provides opportunities for early interactions with the FDA to discuss potential surrogate or intermediate endpoints to support accelerated approval, organizational commitment from senior staff at the agency, opportunities to participate in novel review and development programs, and the potential for a rolling review and priority review of a product's future biologics license application.
Updated clinical data from the BEACON Phase 1/2 clinical trial of BEAM-101 were presented at the European Hematology Association (EHA) 2025 Congress in June, providing further demonstration of the strong clinical profile for BEAM-101, as initially established in previously announced data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. Updated data from 17 patients treated with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet engraftment, and normalized or improved markers of hemolysis and oxygen delivery. BEAM-101 is manufactured using an advanced, largely automated process that has demonstrated consistently high yields and viability.
Beam previously announced that the FDA granted orphan drug designation to BEAM-101 in June, and the company plans to present updated data from the beACON Phase 1/2 trial by the end of 2025.
